Bristol Myers' Sotyktu hits key goals in late-stage PsA trial, fueling hopes for expansion amid recent pipeline setbacks.

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

Bristol MyersBMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

Sotyktu was well tolerated through Week 52, demonstrating a safety profile consistent with previous results of Sotyktu in PsA and PsO. Bristol Myers Squibb will work with key investigators to present ...

Bristol Myers BMY announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint. Sotyktu is an oral, selective tyrosine ...

Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales. The National Institute for ...

One important element of the FDA approval of Sotyktu is its label does not require patients to have tried a biologic therapy first, making it an option for previously-untreated cases.

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.